Bococizumab is a novel anti-PCSK9 antibody specifically developed to combat hypercholesterolemia. This therapeutic agent interacts with the PCSK9 protein, a critical regulator of cholesterol amounts. By inhibiting the https://elainewmaa355921.activoblog.com/51027910/bococizumab-a-novel-anti-pcsk9-antibody-for-hypercholesterolemia